Search Within

Matthew J Matasar

Formats
  1. Meeting Abstract (192)
  2. Journal Article (86)
  3. Book Section (4)
  4. Review (3)
  5. Correspondence (2)
  6. Editorial (2)
  7. Research Letter (2)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (293)
  2. Department of Medicine (293)
  3. Hematologic Malignancies, Division of (293)
  4. Lymphoma (293)
  5. Survivorship Research (293)
  6. Population Sciences Research Program (113)

More Groups

People
  1. Andrew Zelenetz (118)
  2. David Straus (104)
  3. Ariela Noy (101)
  4. Paul Hamlin (100)
  5. Steven Horwitz (98)
  6. Alison Moskowitz (96)

More People

Years
  1. 2024 (9)
  2. 2023 (12)
  3. 2022 (43)
  4. 2021 (43)
  5. 2020 (23)
  6. 2019 (34)

More Years

Publications
  1. Blood (110)
  2. Journal of Clinical Oncology (37)
  3. Hematological Oncology (22)
  4. Biology of Blood and Marrow Transplantation (11)
  5. Clinical Lymphoma, Myeloma and Leukemia (11)
  6. Blood Advances (10)

More Publications

Publishers
  1. American Society of Hematology (120)
  2. American Society of Clinical Oncology (37)
  3. Elsevier Inc. (29)
  4. Wiley Blackwell (26)
  5. Oxford University Press (13)
  6. John Wiley & Sons (10)

More Publishers

Results (293)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Duration of objective responses for patients with indolent non-Hodgkin lymphoma discontinuing treatment before progression: Analysis from the phase III CHRONOS-3 trial comparing copanlisib plus rituximab with placebo plus rituximab
    Meeting Abstract

    Matasar, M. J.; Capra, M.; Özcan, M.; Lv, F.; Li, W.; Yañez, E.; Sapunarova, K.; Lin, T.; Jin, J.; Jurczak, W.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • POLARGO: Randomized phase III study of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in relapsed/refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Matasar, M. J.; Haioun, C.; Sancho, J. M.; Viardot, A.; Hirata, J.; Perretti, T.; Musick, L.; McMillan, A. K.
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg type treated in the rituximab era: Long-term follow-up of a single-center experience
    Meeting Abstract

    Falchi, L.; Qiu, A.; Ewalt, M. D.; Batlevi, C. L.; Caron, P. C.; Hamlin, P. A.; Hamilton, A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥ 2 prior lines of therapy: Pivotal results from a phase I/II study
    Meeting Abstract

    Budde, L. E.; Sehn, L. H.; Matasar, M. J.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impact of choice of platinum-based salvage therapy on CNS relapse in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Buege, M. J.; Dao, P.; Dematteo, R. G.; LeVoir, A.; Pak, T.; Batlevi, C. L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 1 dose escalation study of IGM-2323, a novel anti-CD20 x anti-CD3 IgM T cell engager (TCE) in patients with advanced B-cell malignancies
    Meeting Abstract

    Budde, E.; Gopal, A. K.; Kim, W. S.; Flinn, I. W.; Cheah, C. Y. Y.; Nastoupil, L.; Matasar, M. J.; Diefenbach, C. S.; Gregory, G. P.; Qazi, I.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Subcutaneous (SC) administration of mosunetuzumab with cycle 1 step-up dosing is tolerable and active in patients with relapsed/refractory B-cell non-Hodgkin lymphomas (R/R B-NHL): Initial results from a phase I/II study
    Meeting Abstract

    Bartlett, N. L.; Giri, P.; Budde, L. E.; Schuster, S. J.; Assouline, S.; Matasar, M. J.; Yoon, S. S.; Canales, M.; Gutierrez, N. C.; Fay, K.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: Updated results of a phase Ib/II randomized study and preliminary results of a Single-arm extension
    Meeting Abstract

    Sehn, L. H.; Hess, G.; Hertzberg, M.; Opat, S.; Herrera, A. F.; Assouline, S.; Flowers, C. R.; Kim, T. M.; McMillan, A.; Ozcan, M.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)
    Meeting Abstract

    Dreyling, M.; Matasar, M. J.; Capra, M.; Özcan, M.; Lv, F.; Li, W.; Yanez, E.; Sapunarova, K.; Lin, T.; Jin, J.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save